Biogen downgraded to Neutral from Overweight at Piper Jaffray

theflyonthewall.com

Piper Jaffray downgraded Biogen citing valuation and high expectations for the upcoming launch of BG-12. The firm lowered its price target for shares to $166 from $175.

View Comments (1)